Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triple intralesional antigen immunotherapy (PPD + Candida + MMR)
- Development stage
- Unknown
- Lead developer
- Zagazig University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intralesional
01
Overview
Triple intralesional antigen immunotherapy is an experimental combination biologic treatment developed by researchers at Zagazig University for the management of recalcitrant extragenital warts. The therapy involves the intralesional injection of three distinct antigens: purified protein derivative (PPD), Candida antigen, and the measles-mumps-rubella (MMR) vaccine. The mechanism of action relies on inducing a localized delayed-type hypersensitivity reaction at the site of the largest wart, which triggers a systemic cell-mediated immune response. This immune activation facilitates the recognition and destruction of human papillomavirus (HPV) infected cells, leading to the clearance of both treated and distant warts. Clinical trials have demonstrated that this triple-antigen approach is significantly more effective than using any of the antigens individually, particularly in patients with warts that have failed multiple prior therapeutic modalities.
- Other names
- PPD + Candida + MMR immunotherapyTriple intralesional antigen immunotherapyIntralesional antigen immunotherapy
Beyond the preview
Go deeper on triple intralesional antigen immunotherapy (PPD + Candida + MMR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triple intralesional antigen immunotherapy (PPD + Candida + MMR).